Literature DB >> 30222202

Intestinal barrier integrity in patients with plaque psoriasis.

Mariusz Sikora1, Magdalena Chrabąszcz1, Cezary Maciejewski1, Michał Zaremba1, Anna Waśkiel1, Małgorzata Olszewska1, Lidia Rudnicka1.   

Abstract

Psoriasis is a chronic inflammatory systemic disease. Growing evidence suggests that human homeostasis depends on a mutualistic relationship with gut bacteria that produce a number of biologically active compounds. Therefore, enteric microbiota dysbiosis with gut barrier disruption may be an important factor in the development of chronic inflammatory diseases. The aim of our study was to assess non-invasive markers of intestinal barrier integrity in patients with moderate to severe psoriasis. Concentrations of claudin-3 (intestinal epithelial tight junction structure) and intestinal fatty acid binding protein (I-FABP; marker of enterocyte damage) were determined in the blood of patients with chronic plaque psoriasis (n = 20) and healthy individuals (n = 20) using commercially available enzyme-linked immunoassay test kits. Claudin-3 concentration was higher in patients with psoriasis compared with healthy control (median, 54.07 vs 42.36 ng/mL; P < 0.001). Patients with psoriasis also had elevated concentration of plasma I-FABP (median, 708.8 vs 147.1 pg/mL; P < 0.05). Our results support the hypothesis that dysfunction of the intestinal barrier in psoriasis disturbs the homeostatic equilibrium between the microbiota and immune system. Further studies are needed in order to develop new therapeutic interventions based on modulation of intestinal permeability.
© 2018 Japanese Dermatological Association.

Entities:  

Keywords:  claudin-3; intestinal barrier; intestinal fatty acid-binding protein; microbiome; psoriasis

Mesh:

Substances:

Year:  2018        PMID: 30222202     DOI: 10.1111/1346-8138.14647

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  13 in total

Review 1.  Can intestinal microbiota and circulating microbial products contribute to pulmonary arterial hypertension?

Authors:  Thenappan Thenappan; Alexander Khoruts; Yingjie Chen; E Kenneth Weir
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-09-06       Impact factor: 4.733

Review 2.  Psoriasis and Gut Microbiome-Current State of Art.

Authors:  Karina Polak; Beata Bergler-Czop; Michał Szczepanek; Kamila Wojciechowska; Aleksandra Frątczak; Norbert Kiss
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

3.  Short-Term Western Diet Intake Promotes IL-23‒Mediated Skin and Joint Inflammation Accompanied by Changes to the Gut Microbiota in Mice.

Authors:  Zhenrui Shi; Xuesong Wu; Clarissa Santos Rocha; Matthew Rolston; Emma Garcia-Melchor; Mindy Huynh; Mimi Nguyen; Timothy Law; Kelly N Haas; Daisuke Yamada; Neal L Millar; Yu-Jui Yvonne Wan; Satya Dandekar; Samuel T Hwang
Journal:  J Invest Dermatol       Date:  2021-01-22       Impact factor: 7.590

4.  Clinical Implications of Intestinal Barrier Damage in Psoriasis.

Authors:  Mariusz Sikora; Albert Stec; Magdalena Chrabaszcz; Joanna Giebultowicz; Emilia Samborowska; Radoslaw Jazwiec; Michal Dadlez; Malgorzata Olszewska; Lidia Rudnicka
Journal:  J Inflamm Res       Date:  2021-01-27

Review 5.  Skin and Gut Microbiome in Psoriasis: Gaining Insight Into the Pathophysiology of It and Finding Novel Therapeutic Strategies.

Authors:  Lihui Chen; Jie Li; Wu Zhu; Yehong Kuang; Tao Liu; Wei Zhang; Xiang Chen; Cong Peng
Journal:  Front Microbiol       Date:  2020-12-15       Impact factor: 5.640

Review 6.  Implication of Human Bacterial Gut Microbiota on Immune-Mediated and Autoimmune Dermatological Diseases and Their Comorbidities: A Narrative Review.

Authors:  Roberta Colucci; Silvia Moretti
Journal:  Dermatol Ther (Heidelb)       Date:  2021-01-28

Review 7.  Gut Microbiome in Psoriasis: An Updated Review.

Authors:  Mariusz Sikora; Albert Stec; Magdalena Chrabaszcz; Aleksandra Knot; Anna Waskiel-Burnat; Adriana Rakowska; Malgorzata Olszewska; Lidia Rudnicka
Journal:  Pathogens       Date:  2020-06-12

8.  Trimethylamine N-Oxide, a Gut Microbiota-Derived Metabolite, Is Associated with Cardiovascular Risk in Psoriasis: A Cross-Sectional Pilot Study.

Authors:  Mariusz Sikora; Norbert Kiss; Albert Stec; Joanna Giebultowicz; Emilia Samborowska; Radoslaw Jazwiec; Michal Dadlez; Malgorzata Olszewska; Lidia Rudnicka
Journal:  Dermatol Ther (Heidelb)       Date:  2021-05-13

Review 9.  Aberrations in Lipid Expression and Metabolism in Psoriasis.

Authors:  Julia Nowowiejska; Anna Baran; Iwona Flisiak
Journal:  Int J Mol Sci       Date:  2021-06-18       Impact factor: 5.923

Review 10.  Metabolic Syndrome and Psoriasis: Mechanisms and Future Directions.

Authors:  Yan Hao; Ya-Juan Zhu; Song Zou; Pei Zhou; Ya-Wen Hu; Qi-Xiang Zhao; Lin-Na Gu; Hao-Zhou Zhang; Zhen Wang; Jiong Li
Journal:  Front Immunol       Date:  2021-07-23       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.